91 results on '"Martins, Renato G."'
Search Results
52. A phase I clinical trial of AZD1775 in combination with neoadjuvant weekly cisplatin and docetaxel in borderline resectable head and neck squamous cell carcinoma (HNSCC).
53. Prognostic significance of performance status in patients with head and neck squamous cell carcinomas (HNSCC) receiving immune checkpoint monoclonal antibodies (ICmAB) in a single institution.
54. Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN
55. Clinic level variation in emergency department and inpatient utilization in a community setting.
56. Costs of potentially preventable emergency department use during cancer treatment: A regional study.
57. A Phase 2 Trial of the Multi-targeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer (MTC)
58. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated t
59. Tissue Is the Issue for Diagnosis of EGFR T790M Mutation
60. Value-Based Care in Lung Cancer
61. Racial disparity in oncologic and patient-reported quality of life (PROs) outcomes in patients with locally advanced head and neck squamous cell carcinomas (HNSCC) enrolled in a randomized phase II trial.
62. A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer
63. Salivary Gland Malignancies
64. Dual PD1 and CTLA4 immune checkpoint blockade and hypofractionated radiation in patients with salivary gland cancers.
65. Beyond “Second-Line” in Non–Small Cell Lung Cancer: Therapy and Supportive Care
66. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer
67. Motesanib diphosphate in progressive differentiated thyroid cancer.
68. The Role of Chemotherapy in the Management of Stage IIIA Non-Small Cell Lung Cancer
69. Cisplatin and Radiotherapy With or Without Erlotinib in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Phase II Trial
70. Squamous cell carcinoma of the oral tongue in a patient with Fanconi anemia treated with radiotherapy and concurrent cetuximab: A case report and review of the literature
71. How Do I Treat Patients with Metastatic NSCLC?
72. The Management of Patients With Stage IIIA Non–Small Cell Lung Cancer With N2 Mediastinal Node Involvement
73. Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer
74. Phase II Study of Daily Sunitinib in FDG-PET–Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation
75. Maintenance Chemotherapy in Non–Small Cell Lung Cancer
76. Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer
77. Thymic Carcinoma Associated With Paraneoplastic Polymyositis
78. Phase I Trial of Erlotinib Combined with Cisplatin and Radiotherapy for Patients with Locally Advanced Cervical Squamous Cell Cancer
79. Response to paclitaxel in adenoid cystic carcinoma of the salivary glands
80. First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations
81. Antagonism of Platelet-Derived Growth Factor Receptor in Non–Small Cell Lung Cancer: Rationale and Investigations
82. Novel Agents in the Treatment of Lung Cancer: Fourth Cambridge Conference
83. Docetaxel em administração semanal como quimioterapia de primeira linha para câncer de pulmão de não-pequenas células em estádio IV: tratamento eficaz com toxicidade baixa
84. EFFICACY, SAFETY, AND PATIENT-REPORTED OUTCOMES OF FIRST-LINE DACOMITINIB (PF-00299804), AN IRREVERSIBLE PAN-HER TYROSINE KINASE INHIBITOR, IN PATIENTS WITH LUNG CANCERS HARBORING EGFR EXON 21 MUTATION OR EGFR EXON 19 DELETION
85. PHASE 2 DATA FOR CRIZOTINIB (PF-02341066) IN ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): PROFILE 1005
86. Tissue Is the Issue for Diagnosis of EGFRT790M Mutation
87. Thymic Carcinoma Associated With Paraneoplastic Polymyositis.
88. Management of thyroid cancer of follicular cell origin: Gundersen/Lutheran Medical Center, 1969–1995
89. Prognostic Value of Early Fluorodeoxyglucose-Positron Emission Tomography Response Imaging and Peripheral Immunologic Biomarkers: Substudy of a Phase II Trial of Risk-Adaptive Chemoradiation for Unresectable Non-Small Cell Lung Cancer.
90. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020.
91. Second-line and third-line chemotherapy for lung cancer: use and cost.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.